About this trial
The goal of this study is to evaluate the effects of nutritional supplementation and physical activity interventions on recovery, muscle strength, nutritional status, inflammation, and metabolic health in adults with colon cancer undergoing surgery.
Patients with colon cancer frequently experience loss of muscle mass, reduced physical function, and nutritional deterioration both before and after surgery, which may adversely affect recovery and quality of life.
A key objective of this study is to assess whether a postoperative intervention combining nutritional supplementation with beta-hydroxy beta-methylbutyrate (HMB) and vitamin D, together with a structured physical activity program, can improve muscle strength and functional recovery following colon cancer surgery.
This study aims to answer the following questions:
* Does nutritional supplementation with HMB and vitamin D, combined with postoperative physical activity, improve muscle strength and physical function following colon cancer surgery? * How do nutritional and lifestyle interventions influence nutritional status, gut microbiota composition, and biological markers of inflammation and metabolism during the recovery period? * Are there differences in recovery outcomes between patients receiving different types of nutritional support, with or without supervised physical activity?
Participants will be adults diagnosed with colon cancer who undergo surgical treatment at the Hospital Universitario Virgen de la Victoria in Málaga, Spain. Patients will be recruited prior to surgery and will enter a prehabilitation phase integrated into routine care provided by the Endocrinology and Nutrition Department.
During this prehabilitation phase, nutritional status will be assessed and optimized using standard clinical care, including oral nutritional supplementation when indicated. The aim is to improve the patient's condition before surgery. Approximately one month after surgery, once initial postoperative recovery has been completed, participants will enter the intervention and assessment phase (baseline visit).
Participants will then be randomly assigned to one of four study groups in a 2×2 factorial design. These groups combine two nutritional strategies (standard care or supplementation with HMB and vitamin D) and two physical activity approaches (supervised exercise or general activity recommendations). The physical activity component, supervised by the Endocrinology and Nutrition team, will be objectively evaluated using an accelerometer-based device. Participants will be followed for approximately six months, with assessments at about 3 and 6 months after the baseline visit.
At each visit, participants will undergo:
* Body composition measurements * Muscle strength and physical performance tests * Collection of blood, urine, and stool samples * Questionnaires on health status and quality of life
The results of this study will contribute to a more profound understanding of how tailored nutritional strategies and postoperative physical activity may support recovery and functional health in patients undergoing surgery for colon cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18 to 75 years.
Male and female participants.
Diagnosis of colon cancer at localized or locally advanced stages (TNM stages I-III).
Patients scheduled for primary surgical treatment.
Disqualifiers
Metastatic disease (stage IV)
Diagnosis of rectal cancer or tumors involving the rectum
Prior neoadjuvant chemotherapy or radiotherapy before surgery.
Presence of synchronous malignant tumors.
Trial design
Factorial
Treatments tested in this trial
Standard hypercaloric-hyperproteic nutritional supplementation
Dietary supplementParticipants receive a standard oral nutritional supplementation consisting of a hypercaloric and hyperproteic formula designed to support recovery and nutritional status in patients undergoing surgery.
HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium
Dietary supplementParticipants receive an oral hypercaloric and hyperproteic nutritional supplementation enriched with β-hydroxy β-methylbutyrate (HMB) and supplemented with vitamin D and calcium. This formulation is designed to support muscle mass preservation and functional recovery in patients undergoing surgical treatment.
Supervised exercise program
BehavioralParticipants follow a structured and supervised physical activity program including resistance exercises and functional training. Physical activity levels are periodically monitored using wearable activity devices.
General physical activity recommendations
BehavioralParticipants receive general recommendations for physical activity according to routine clinical practice but do not participate in the structured supervised exercise program.
Treatment groups
Trial outcomes
Primary outcomes
Change in phase angle (PhA)
Phase angle will be assessed by bioelectrical impedance analysis (BIA) as a bioelectrical marker of nutritional and cellular status. Results will be expressed in degrees.
Change in quadriceps rectus femoris cross-sectional area
Muscle mass will be assessed using nutritional ultrasound by measuring the cross-sectional area of the quadriceps rectus femoris at a standardized anatomical site (cm²).
Secondary outcomes
Plasma concentration of inflammatory and metabolic biomarkers measured by multiplex immunoassay
Plasma concentrations of selected biomarkers (including adiponectin, FABP-3, FGF-21, BDNF, IL-6, IL-15, TNF-α, and MCP-1) will be measured using multiplex immunoassay technology (Bio-Plex MAGPIX / Luminex xMAP). Each biomarker will be analyzed as an individual continuous variable and expressed in pg/mL.
Percentage of DNA methylation in peripheral blood mononuclear cells (PBMCs)by quantitative PCR
DNA methylation levels will be assessed in peripheral blood mononuclear cells (PBMCs) using bisulfite conversion followed by quantitative PCR. Results will be expressed as the percentage of methylated cytosines at CpG sites.
Change in urinary oxylipin concentrations by UHPLC-MS/MS
Selected oxylipins, including isoprostanes, prostaglandins, and thromboxane, will be quantified in first-morning urine samples using targeted ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-QqQ-MS/MS). Results will be expressed as concentrations normalized to urinary creatinine (e.g., ng/mg creatinine).
Change in relative abundance of gut microbiota taxa
Gut microbiota composition will be assessed in stool samples using 16S rRNA gene sequencing. Relative abundance of bacterial taxa will be quantified at different taxonomic levels (e.g., phylum, genus) and expressed as percentages (%) of total sequencing reads per sample.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Lead sponsor
Instituto de Salud Carlos III
Collaborator